|
Oct 14
|
Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug
|
|
Oct 14
|
Hims & Hers to Announce Third Quarter 2024 Financial Results on November 4, 2024
|
|
Oct 14
|
Hims & Hers surges as FDA mulls over compounded drugs limit
|
|
Oct 10
|
WeightWatchers stock soars, but its cheap Wegovy knockoff 'is not a sustainable long-term business model'
|
|
Oct 4
|
Hims & Hers Health Set to Join S&P SmallCap 600
|
|
Oct 4
|
Eli Lilly's Mounjaro, Zepbound removed from FDA's shortage list
|
|
Oct 3
|
For Hims & Hers Stock, GLP-1 Giveth and GLP-1 Taketh Away
|
|
Oct 3
|
Stocks to Watch Thursday: Levi Strauss, Hims & Hers, Constellation Brands, Nvidia
|
|
Oct 3
|
Hims & Hers stock falls after Eli Lilly's weight-loss drug dropped from shortage list
|
|
Jul 31
|
Hims & Hers Health Stock Flashing Buy Signal Before Earnings
|
|
Jun 27
|
Heard on the Street Wednesday Recap: Land of the Rising Sum
|
|
Jun 26
|
The War Over Cheaper Ozempic Won’t End Well for Some Investors
|
|
Jun 13
|
Explore These 3 US Growth Companies With High Insider Ownership
|
|
May 20
|
Investors await Nvidia earnings, commodities on the rise: Morning Brief
|
|
May 20
|
Heard on the Street: Hims Is Jumping on a Crowded Ozempic Bandwagon
|
|
May 20
|
Hims & Hers Health to Offer Injectable Weight-Loss Drugs on Telehealth Platform
|
|
May 20
|
Weight loss: Hims & Hers introduce access to GLP-1 injections
|
|
May 20
|
Hims & Hers Announces Access to GLP-1 Injections, Passing Cost Savings Onto Customers
|
|
May 16
|
Hims & Hers Welcomes Anja Manuel, Foreign Policy Expert, Domestic Regulations Advisor, and Former Diplomat to its Board of Directors
|
|
May 15
|
High Insider Ownership Growth Stocks On US Exchange For May 2024
|